[go: up one dir, main page]

MA39163B1 - Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine - Google Patents

Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Info

Publication number
MA39163B1
MA39163B1 MA39163A MA39163A MA39163B1 MA 39163 B1 MA39163 B1 MA 39163B1 MA 39163 A MA39163 A MA 39163A MA 39163 A MA39163 A MA 39163A MA 39163 B1 MA39163 B1 MA 39163B1
Authority
MA
Morocco
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
MA39163A
Other languages
English (en)
Other versions
MA39163A1 (fr
Inventor
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Markus Gude
Jodi Williams
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA39163A1 publication Critical patent/MA39163A1/fr
Publication of MA39163B1 publication Critical patent/MA39163B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des formes cristallines de (s)-(2-(6-chloro-7-méthyl-1h-benzo[d]imidazol-2- yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation de celles-ci, des compositions pharmaceutiques contenant de telles formes cristallines, des compositions pharmaceutiques préparées à partir de telles formes cristallines ainsi que leur utilisation en tant que médicament, notamment en tant qu'antagonistes des récepteurs de l'orexine.
MA39163A 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine MA39163B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
PCT/IB2014/066508 WO2015083070A1 (fr) 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Publications (2)

Publication Number Publication Date
MA39163A1 MA39163A1 (fr) 2017-11-30
MA39163B1 true MA39163B1 (fr) 2018-09-28

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39163A MA39163B1 (fr) 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Country Status (31)

Country Link
US (1) US9914720B2 (fr)
EP (1) EP3077389B1 (fr)
JP (1) JP6496733B2 (fr)
KR (1) KR102361418B1 (fr)
CN (1) CN105793257B (fr)
AU (1) AU2014358742B2 (fr)
CA (1) CA2929423C (fr)
CL (1) CL2016001342A1 (fr)
CY (1) CY1119695T1 (fr)
DK (1) DK3077389T3 (fr)
EA (1) EA030137B1 (fr)
ES (1) ES2651475T3 (fr)
HK (1) HK1225731B (fr)
HR (1) HRP20171773T1 (fr)
HU (1) HUE035731T2 (fr)
IL (1) IL245923B (fr)
LT (1) LT3077389T (fr)
MA (1) MA39163B1 (fr)
MX (1) MX364208B (fr)
MY (1) MY179862A (fr)
NO (1) NO3077389T3 (fr)
NZ (1) NZ721438A (fr)
PH (1) PH12016500988A1 (fr)
PL (1) PL3077389T3 (fr)
PT (1) PT3077389T (fr)
SA (1) SA516371231B1 (fr)
SI (1) SI3077389T1 (fr)
TW (1) TWI664177B (fr)
UA (1) UA119549C2 (fr)
WO (1) WO2015083070A1 (fr)
ZA (1) ZA201604499B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703448A (en) * 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
JP7182562B2 (ja) * 2017-05-03 2022-12-02 イドーシア ファーマシューティカルズ リミテッド ２－（［１，２，３］トリアゾール－２－イル）－安息香酸誘導体の製造
US20230134935A1 (en) 2020-04-19 2023-05-04 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
US20240300925A1 (en) * 2021-02-02 2024-09-12 Medshine Discovery Inc. Tetrahydropyrrolocyclic compound and application thereof
WO2023160004A1 (fr) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 Composé à cycle fusionné ayant une activité analgésique, son procédé de préparation et son utilisation

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
US7432270B2 (en) 2001-05-05 2008-10-07 Smithkline Beecham P.L.C. N-aroyl cyclic amines
WO2002089800A2 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MXPA03011706A (es) * 2001-06-28 2004-03-19 Smithkline Beecham Plc Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina.
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
ATE344261T1 (de) 2002-09-18 2006-11-15 Glaxo Group Ltd Cyclische n-aroylamine als orexinrezeptorantagonisten
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
DK1751111T3 (en) 2004-03-01 2015-02-09 Actelion Pharmaceuticals Ltd SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives
UA93903C2 (ru) 2006-03-15 2011-03-25 Актелион Фармасьютикалз Лтд Производные тетрагидроизохинолина для повышения функции памяти
WO2007135527A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés de benzimidazolyle
PL2069332T3 (pl) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
EP2079690B1 (fr) 2006-09-29 2010-09-15 Actelion Pharmaceuticals Ltd. Derives du 3-aza-bicyclo[3.1.0]hexane
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (fr) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Dérivés de pyrrolidine et de piperidine
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
KR20100041805A (ko) 2007-07-03 2010-04-22 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.3.0]옥탄 화합물
TW200911242A (en) 2007-07-03 2009-03-16 Glaxo Group Ltd Novel compounds
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
RU2478099C2 (ru) 2007-07-27 2013-03-27 Актелион Фармасьютиклз Лтд Производные 2-аза-бицикло[3.3.0]октана
JP2010534646A (ja) 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド トランス−３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
AU2009215243A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (fr) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine
JP2012509911A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060472A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de l’imidazopyridazine agissant en tant qu’antagonistes de l’orexine
EP2358711A1 (fr) 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu antagonistes du récepteur de l orexine
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
CN103201261A (zh) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 用作为食欲素受体拮抗剂的内酰胺衍生物
EP2675801B1 (fr) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Nouveaux dérivés de pyrazole et d'imidazole utiles à titre d'antagonistes d'orexine
US9150566B2 (en) 2011-11-08 2015-10-06 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
NZ703448A (en) * 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (fr) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну

Also Published As

Publication number Publication date
DK3077389T3 (da) 2017-11-13
CN105793257B (zh) 2018-11-13
AU2014358742A1 (en) 2016-07-07
KR102361418B1 (ko) 2022-02-09
EP3077389A1 (fr) 2016-10-12
KR20160092015A (ko) 2016-08-03
EP3077389B1 (fr) 2017-09-13
US20160368901A1 (en) 2016-12-22
HK1225731B (zh) 2017-09-15
EA201600435A1 (ru) 2016-11-30
IL245923B (en) 2019-09-26
PT3077389T (pt) 2017-12-15
ES2651475T3 (es) 2018-01-26
MY179862A (en) 2020-11-18
LT3077389T (lt) 2017-12-11
US9914720B2 (en) 2018-03-13
MX364208B (es) 2019-04-16
TW201605838A (zh) 2016-02-16
EA030137B1 (ru) 2018-06-29
JP6496733B2 (ja) 2019-04-03
NZ721438A (en) 2021-12-24
BR112016012628A2 (fr) 2017-08-22
BR112016012628A8 (pt) 2017-12-26
CA2929423C (fr) 2021-12-07
HRP20171773T1 (hr) 2017-12-29
ZA201604499B (en) 2019-04-24
IL245923A0 (en) 2016-08-02
MX2016007215A (es) 2016-09-07
CY1119695T1 (el) 2018-04-04
SA516371231B1 (ar) 2018-02-20
CA2929423A1 (fr) 2015-06-11
CL2016001342A1 (es) 2016-11-18
CN105793257A (zh) 2016-07-20
NO3077389T3 (fr) 2018-02-10
PH12016500988B1 (en) 2016-06-20
UA119549C2 (uk) 2019-07-10
PH12016500988A1 (en) 2016-06-20
JP2016539136A (ja) 2016-12-15
AU2014358742B2 (en) 2019-02-07
SI3077389T1 (en) 2018-01-31
WO2015083070A1 (fr) 2015-06-11
HUE035731T2 (hu) 2018-05-28
MA39163A1 (fr) 2017-11-30
TWI664177B (zh) 2019-07-01
PL3077389T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
IN2012DN02177A (fr)
IN2012DN02702A (fr)
IN2012DN00754A (fr)
MX2011012839A (es) Antagonistas policiclicos de receptores de acido lisofosfatidico.
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA29816B1 (fr) Composes de benzimidazole thiophene
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA97826C2 (ru) Быстро диссоциирующие антагонисты рецептора 2 дофамина
MX2010009574A (es) 2-aminoquinolinas.
MA38358A1 (fr) Formulations de composés organiques
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EA200970553A1 (ru) Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
PE20190382A1 (es) Derivados etinilo
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
UA101367C2 (en) Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS